Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer

(2010) C Dive et al.   BRITISH JOURNAL OF CANCER

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

(2009) Jian-Mei Hou et al.   AMERICAN JOURNAL OF PATHOLOGY

Circulating cell death products predict clinical outcome of colorectal cancer patients

(2009) Pim J Koelink et al.   BMC CANCER

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response

(2009) L C Scott et al.   BRITISH JOURNAL OF CANCER

Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients

(2009) C. Ausch et al.   EJSO

Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors

(2009) Banu Ozturk et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Molecular imaging of cell death

(2009) Marijke De Saint-Hubert et al.   METHODS

Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer

(2008) D. Micha et al.   CLINICAL CANCER RESEARCH

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

(2008) J. Cummings et al.   MOLECULAR CANCER THERAPEUTICS